Immutep Limited (ASX:IMM) Announces Positive Phase I Results for IMP761
Immutep (ASX:IMM) reports positive Phase I results for IMP761, showing significant T cell suppression and favourable safety profile.
Category: ASX-IMM
Immutep Limited
Immutep Limited (ASX:IMM) Reports Q3 FY25 Milestones and Financial Position
Immutep Limited (ASX:IMM) announces significant clinical trial milestones and maintains a robust cash position in its Q3 FY25 report.
Immutep Limited (ASX:IMM) Initiates Phase III Trial for Non-Small Cell Lung Cancer
Immutep Limited (ASX:IMM) initiates pivotal Phase III trial for non-small cell lung cancer, aiming to establish new treatment standards.